ADRB2 and non-small cell lung carcinoma: In NSCLC, Nilsson and colleagues described a mechanism of resistance to anti-epidermal growth factor receptor (EGFR) inhibition involving beta 2-adrenergic receptors (β2-AR) signaling [53].